Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs
Open Access
- 8 August 2008
- journal article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 12 (02) , 227-241
Abstract
Schizophrenia symptoms segregate into positive, negative and cognitive, which exhibit differential sensitivity to drugs. Recent efforts to identify trKeywords
This publication has 105 references indexed in Scilit:
- Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of SchizophreniaArchives of General Psychiatry, 2005
- Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidolPsychopharmacology, 2003
- The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatmentPsychopharmacology, 2003
- GlycineB Receptor Antagonists and Partial Agonists Prevent Memory Deficits in Inhibitory Avoidance LearningNeurobiology of Learning and Memory, 2000
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996
- Scopolamine Selectively Disrupts the Acquisition of Contextual Fear Conditioning in RatsNeurobiology of Learning and Memory, 1995
- Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug actionPsychopharmacology, 1993
- Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposurePsychopharmacology, 1993
- Glycine-evoked release of [3H]acetylcholine from rat striatal slices is independent of the NMDA receptorNaunyn-Schmiedeberg's Archives of Pharmacology, 1988
- PhysostigmineArchives of General Psychiatry, 1975